Form 4: Alnylam Pharmaceuticals Director Amy Schulman Executes Stock Option and Sells Shares Under 10b5-1 Plan

Director Amy Schulman exercised stock options and sold shares of Alnylam Pharmaceuticals under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On June 25, 2024, Amy Schulman, a director of Alnylam Pharmaceuticals, exercised a stock option to acquire 8,500 shares of common stock at a price of $131.21 per share.
• Simultaneously, Schulman sold 8,500 shares of Alnylam common stock at a price of $240 per share.
• These transactions were executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on February 28, 2024.
• Following these transactions, Schulman directly owns 8,436 shares of Alnylam common stock and 2,750 stock options.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company directors and officers, which is important for maintaining investor confidence.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the director's sale of shares, but the pre-arranged trading plan mitigates concerns about opportunistic trading.

Key Dates